PO-120: Head and neck cancers are associated with poor EQ-5D-related utility in France (EPICORL study)

Schwarzinger, Michaël; Huguet, F.; Temam, Stéphane; Pointreau, Y.; Bec, M.; Even, Caroline; Geoffrois, L.; Lévy-Bachelot, L.; Luchini, Stefania

doi:10.1016/s0167-8140(17)30254-2

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sixty percent of head and neck squamous cell carcinomas (HNSCC) are diagnosed at locally advanced stages [ 1 ]. Until the early 1990s, local treatments (surgery and/or radiotherapy [RT]) were the key components of treatment for locally advanced head and neck cancers (LAHNC) [ 2 , 3 ] with a high rates of relapse and morbidity [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers

et al. 2021

View full text Add to dashboard Cite

Background The rate of toxic deaths related to induction chemotherapy in the treatment of locally advanced head and neck cancers is unacceptable and calls into question this therapeutic strategy, which is however highly effective in terms of rate and speed of response. The purpose of the study was to investigate predictive factors of toxicity of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) in locally advanced head and neck cancers (LAHNC). Methods Between June 2009 and December 2017, 113 patients treated consecutively with TPF were included retrospectively. Patients were receiving induction chemotherapy for either an inoperable cancer or laryngeal preservation. For inoperable cancer, induction chemotherapy was proposed to patients presenting either a large tumor with strong symptoms (dyspnea, dysphagia, pain) or a tumor with rapid progression. Risk factors were chosen among the initial patient and tumour characteristics and chemotherapy modalities. Results Eighty-nine patients (79%) were male; the median age was 58 years [32–71]. Sixty-nine (61%) patients were treated for inoperable cancer and 44 (39%) for laryngeal preservation. 45% had stage IVa cancer, 28% stage III and 25% stage IVb. Sixty percent of patients had a partial response after TPF, 22% had a complete response, 12% were stable, 5% were progressing, and 1% had a discordant response. Thirty-four patients (30%) received enteral feeding during induction chemotherapy with TPF. The possibility of oral feeding without a tube was predictive of a better response (p = 0.003). Seven (6%) patients died during TPF. There was an increased risk of death with preexisting liver dysfunction (liver dysmorphia on imaging or decrease prothrombin rate) (p = 0.032). There was an increased risk of grade ≥ 3 infection if an enteral feeding occurred during the period of induction chemotherapy (p = 0.03). Conclusions TPF induction chemotherapy had an 82% objective response rate with 6% toxic deaths. Nutritional status and the presence of hepatic dysfunction are significant risk factors to be taken into account in therapeutic decisions.

show abstract